Docetaxel chronopharmacology in mice

Cancer Research

Volumn 58, Issue 17, 1998, Pages 3896-3904

  Tampellini, Marco ^a,b   Filipski, Elisabeth ^a   Liu, Xu Hui ^a   Lemaigre, Guy ^a   Li, Xiao Mei ^a   Vrignaud, Patricia ^c   François, Emmanuel ^a   Bissery, Marie Christine ^c   Lévi, Francis ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITY OF TURIN   (Italy)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ETOPOSIDE; NAVELBINE; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL CYCLE; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; INTRAVENOUS DRUG ADMINISTRATION; JEJUNUM; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY WEIGHT; BONE MARROW; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS;

EID: 0032170548     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hrushesky, W. J. M., Bjarnason, G. A. Circadian cancer therapy. J. Clin. Oncol., 11: 1403-1417, 1993.
2. Lévi, F. Chronopharmacology of anticancer agents. In: P. H. Redfem and B. Lemmer (eds.), Handbook of Experimental Pharmacology. Vol. 125: Physiology and Pharmacology of Biological Rhythms pp. 299-331. Springer-Verlag, Berlin, 1997.
3. Li, X. M., Metzger, G., Filipski, E., Boughattas, N., Lemaigre, G., Hecquet, B., Filipski, J., and Lévi, F. Pharmacologic modulation of reduced glutathione (GSH) circadian rhythms by buthionine sulfoximine (BSO): relationship with cisplatin (CDDP) toxidly in mice. Toxicol. Appl. Pharmacol., 43: 281-290, 1997.
4. 6-methylguanine-DNA methyltransferase activity in mouse liver, Anticancer Drugs. 7: 1-7, 1996.
5. Zhang, R., Lu, Z., Liu, T., Soong, S. J., and Diasio, R. B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res., 53: 2816-2822, 1993.
6. Harris, B., Song, R., Soong, S., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
7. Langouët, A. M., Metzger, G., Comisso, M., Renée, N., Milano, G., Mormont, C., and Lévi, F. Plasma drug concentration control through time-programmed administration. Proc. Am. Assoc. Cancer Res., 37: 183, 1996.
8. Lévi, F., Blazsek, L, and Ferlé-Vidovic, A. Circadian and seasonal rhythms in murine bone marrow colony forming cells affect tolerance for the anticancer agent 4′-O-tetrahydropyranyladriamycin (THP). Exp. Hematol., 16: 696-701, 1988.
9. Smaaland, R., Laerum, O. D., Lote, K., Stetvold, O., Sothern, R. B., and Bjerknes, R. DNA synthesis in human bone marrow is circadian stage dependent. Blood. 77: 2603-2611, 1991.
10. Hrushesky, W. J. M. Circadian timing of cancer chemotherapy. Science (Washington DC), 228: 73-75, 1985.
11. Lévi, F., Benavides, M., Chevelle, C., Le Saulnier, F., Bailleul, F., Misset, J. L., Regensberg, C., Vannetzel, J. M., Reinberg, A., and Mathé, G. Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyladriamycin (THP) and cisplatin: a phase II trial with an evaluation of circadian timing and dose intensity. J. Clin. Oncol., 8: 705-714, 1990.
12. Von Roemeling, R., and Hrushesky, W. J. M. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J. Clin. Oncol., 7: 1710-1719, 1989.
13. Caussanel, J. P., Lévi, F., Brienza, S., Misset, J. L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B., and Mathé, G. Phase I trial of 5-day continuous venous infusion of oxaliptatin at circadian rhythm-modulated rate compared with constant rate. J. Natl Cancer Inst., 82: 1046-1050, 1990.
14. Garufi, C., Lévi, F., Aschelter, A. M., Giunta, S., Pace, R., Nistico, C., Tropea, F., Cardamone, I., Silecchia, G. F., and Terzoli, E. A Phase I trial of five day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. Eur. J. Cancer, 33: 1566-1571, 1997.
15. Lévi, F. Chronotherapy for gastrointestinal cancers. Curr. Opin. Oncol., 8: 334-341, 1996.
16. Lévi, F., Zidani, R., Vannetzel, J. M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., lacobelli, S., Adam, R., Kunstlinger, F., Gastiaburu, J., Bismuth, H., Jasmin, C., and Misset, J. L. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J. Natl. Cancer Inst., 86: 1608-1617, 1994.
17. Lévi, F., Zidani, R., Missel, J. L. for the International Organization for Cancer Chronotherapy. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. The Lancet, 350: 681-686, 1997.
18. Fuchs, D. A., and Johnson, R. K. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifoglia, acts as a mitotic spindle poison. Cancer Treat. Rep., 62: 1219-1222, 1978.
19. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 22: 665-667, 1979.
20. Rowinski, E. K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med., 48: 353-374, 1997.
21. Bissery, M. C., Guénard, D., Guéritte-Voegelein, F., and Lavelle, F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res., 51: 4845-4852, 1991.
22. Fromes, Y., Gounon, P., Veitia, R., Bissery, M. C., and Fellous, A. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J. Prot. Chem., 15: 377-388, 1996.
23. Haldar, S., Basu, A., and Croce, C. M. Bcl2 is the guardian of microtubule integrity. Cancer Res., 57: 229-233, 1997.
24. TM) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann. Oncol., 5: 527-532, 1994.
25. TM) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials group (ECTG). Br. J. Cancer, 70: 384-387, 1994.
26. Fossella, F. V., Lee, J. S., Murphy, W. K., Lippman, S. M., Calayag, M., Pang, A., Chanson, M., Shin, D. M., Glisson, B., Benner, S., Huber, M., Perez-Soler, R., Hong, W. K., and Raber, M. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol., 12: 1238-1244, 1994.
27. TM in ovarian cancer. Ann. Oncol., 5: 202, 1994.
28. TM) toxicities: analysis of a single institution experience of 168 patients (623 courses). Proc. Am. Soc. Clin. Oncol., 13: 164, 1994.
29. Lévi, F., Mechkouri, M., Roulon, A., Bailleul, F., Horvath, C., Reinberg, A., and Mathé, G. Circadian rhythm in tolerance of mice for etoposide. Cancer Treat. Rep., 69: 1443-1445, 1985.
30. Tsai, T. H., and Scheving, L. E. Murine circadian variation in susceptibility to 4′-demethyl-epipodophyllotoxin-β-D-ethylidene glucoside (VP 16-213) as well as to the solvent alone in which it was suspended. Ann. Rev. Chronopharmacol., 1: 389-396, 1985.
31. Mormont, C., Berestka, J., Mushiya, T., Langevin, T., von Roemeling, R., Rabatin, J., Sothern, R., and Hrushesky, W. Circadian dependency of vinblastine toxicity. Annu. Rev. Chronopharmacol., 3: 187-190, 1987.
32. Tampellini, M., Filipski, E., and Lévi, F. Circadian variation of Vinorelbine toxicity in mice. Chronobiol. Intern., 12: 195-198, 1995.
33. Corbett, T. H., Roberts, B. J., Leopold, W. R., Peckham, J. C., Wilkoff, L. J., Griswold, D. P., Jr., and Schabel, F. M., Jr. Induction and chemotherapeutic response of two transplantable ductal adenoearcinomas of the pancreas in C57BL6 mice. Cancer Res., 44: 717-726, 1984.
34. Nakahata, H., and Ogawa, M. Identification in culture of a class of hemopoietic colony-forming units with extensive capability to self-renew and generate multipotential hemopoietic colonies. Proc. Natl. Acad. Sci. USA, 79: 3843, 1982.
35. Dean, P., and Jett, J. Mathematical analysis of DNA distributions derived from flow microfluorimetry. J. Cell Biol., 60: 523-527, 1974.
36. Sothern, R., Lévi, F., Haus. E., Halberg, F., and Hrushesky, W. J. M. Control of a murine plasmaeytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J. Natl. Cancer Inst., 81: 135-145, 1989.
37. Filipski, E., Breillout, F., and Lévi, F. Cure rate linked to circadian ltolerability rhythm of vinorelbine in P388 leukemic mice. Proc. Am. Assoc. Cancer Res., 38: 283, 1997.